Skip to main content Help with accessibility Skip to main navigation

June 2022 updates to the website

The website has now been updated following June's LSCMMG

The following guidelines have been added/updated:

Degaralix prescriber information sheet - updated

Hydroxychloroquine prescriber information sheet - updated

Ivabradine prescriber information sheet - updated

Melatonin prescriber information sheet - updated

Clopidogrel tablets after a stroke or mini-stroke information sheet - removed 

Ciclosporin shared care guidance - update to follow 

The following Items have been updated and added to the website following the latest Strategic Commissioning Committee (SCC) Meeting:

Progesterone capsules - Progestogenic opposition of oestrogen HRT in women with an intact uterus

Ozurdex (dexamethasone intravitreal implant) - for adult patients who have visual impairment due to diabetic macular oedema (DME) who are not pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy

Trimbow NEXThaler - COPD

Fremanezumab - preventing migraine (NICE TA764)

Upadacitinib - treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA768)

Palforzia - treating peanut allergy in children and young people (NICE TA769)

Empagliflozin - for treating chronic heart failure with reduced ejection fraction (NICE TA773)

Dapagliflozin - treating chronic kidney disease (NICE TA775)

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Liothyronine - Add-on treatment for refractory hypothyroidism despite adequate replacement with levothyroxine – new patients

Liothyronine - Add-on treatment for refractory hypothyroidism – existing patients.

Liothyronine - Liothyronine monotherapy for the management of chronic hypothyroidism – primary and secondary care